The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?
Overweight and obesity constitute the most impactful lifestyle-dependent risk factors for cancer and have been tightly linked to a higher number of tumor-related deaths nowadays. The excessive accumulation of energy can lead to an imbalance in the level of essential cellular biomolecules that may re...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/11/2709 |
| _version_ | 1797493910758490112 |
|---|---|
| author | Reyes Benot-Dominguez Annamaria Cimini Daniela Barone Antonio Giordano Francesca Pentimalli |
| author_facet | Reyes Benot-Dominguez Annamaria Cimini Daniela Barone Antonio Giordano Francesca Pentimalli |
| author_sort | Reyes Benot-Dominguez |
| collection | DOAJ |
| description | Overweight and obesity constitute the most impactful lifestyle-dependent risk factors for cancer and have been tightly linked to a higher number of tumor-related deaths nowadays. The excessive accumulation of energy can lead to an imbalance in the level of essential cellular biomolecules that may result in inflammation and cell-cycle dysregulation. Nutritional strategies and phytochemicals are gaining interest in the management of obesity-related cancers, with several ongoing and completed clinical studies that support their effectiveness. At the same time, cyclin-dependent kinases (CDKs) are becoming an important target in breast and ovarian cancer treatment, with various FDA-approved CDK4/6 inhibitors that have recently received more attention for their potential role in diet-induced obesity (DIO). Here we provide an overview of the most recent studies involving nutraceuticals and other dietary strategies affecting cell-cycle pathways, which might impact the management of breast and ovarian cancers, as well as the repurposing of already commercialized chemotherapeutic options to treat DIO. |
| first_indexed | 2024-03-10T01:26:46Z |
| format | Article |
| id | doaj.art-63029415f2754245956d321b7ea62317 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T01:26:46Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-63029415f2754245956d321b7ea623172023-11-23T13:49:50ZengMDPI AGCancers2072-66942022-05-011411270910.3390/cancers14112709The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?Reyes Benot-Dominguez0Annamaria Cimini1Daniela Barone2Antonio Giordano3Francesca Pentimalli4Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USADepartment of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, ItalyCell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Napoli, ItalySbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USADepartment of Medicine and Surgery, LUM University, 70010 Bari, ItalyOverweight and obesity constitute the most impactful lifestyle-dependent risk factors for cancer and have been tightly linked to a higher number of tumor-related deaths nowadays. The excessive accumulation of energy can lead to an imbalance in the level of essential cellular biomolecules that may result in inflammation and cell-cycle dysregulation. Nutritional strategies and phytochemicals are gaining interest in the management of obesity-related cancers, with several ongoing and completed clinical studies that support their effectiveness. At the same time, cyclin-dependent kinases (CDKs) are becoming an important target in breast and ovarian cancer treatment, with various FDA-approved CDK4/6 inhibitors that have recently received more attention for their potential role in diet-induced obesity (DIO). Here we provide an overview of the most recent studies involving nutraceuticals and other dietary strategies affecting cell-cycle pathways, which might impact the management of breast and ovarian cancers, as well as the repurposing of already commercialized chemotherapeutic options to treat DIO.https://www.mdpi.com/2072-6694/14/11/2709CDK inhibitors (CDKIs)diet-induced obesity (DIO)ovarian cancerbreast cancercell-cycle inhibitorsRB1 |
| spellingShingle | Reyes Benot-Dominguez Annamaria Cimini Daniela Barone Antonio Giordano Francesca Pentimalli The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers? Cancers CDK inhibitors (CDKIs) diet-induced obesity (DIO) ovarian cancer breast cancer cell-cycle inhibitors RB1 |
| title | The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers? |
| title_full | The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers? |
| title_fullStr | The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers? |
| title_full_unstemmed | The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers? |
| title_short | The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers? |
| title_sort | emerging role of cyclin dependent kinase inhibitors in treating diet induced obesity new opportunities for breast and ovarian cancers |
| topic | CDK inhibitors (CDKIs) diet-induced obesity (DIO) ovarian cancer breast cancer cell-cycle inhibitors RB1 |
| url | https://www.mdpi.com/2072-6694/14/11/2709 |
| work_keys_str_mv | AT reyesbenotdominguez theemergingroleofcyclindependentkinaseinhibitorsintreatingdietinducedobesitynewopportunitiesforbreastandovariancancers AT annamariacimini theemergingroleofcyclindependentkinaseinhibitorsintreatingdietinducedobesitynewopportunitiesforbreastandovariancancers AT danielabarone theemergingroleofcyclindependentkinaseinhibitorsintreatingdietinducedobesitynewopportunitiesforbreastandovariancancers AT antoniogiordano theemergingroleofcyclindependentkinaseinhibitorsintreatingdietinducedobesitynewopportunitiesforbreastandovariancancers AT francescapentimalli theemergingroleofcyclindependentkinaseinhibitorsintreatingdietinducedobesitynewopportunitiesforbreastandovariancancers AT reyesbenotdominguez emergingroleofcyclindependentkinaseinhibitorsintreatingdietinducedobesitynewopportunitiesforbreastandovariancancers AT annamariacimini emergingroleofcyclindependentkinaseinhibitorsintreatingdietinducedobesitynewopportunitiesforbreastandovariancancers AT danielabarone emergingroleofcyclindependentkinaseinhibitorsintreatingdietinducedobesitynewopportunitiesforbreastandovariancancers AT antoniogiordano emergingroleofcyclindependentkinaseinhibitorsintreatingdietinducedobesitynewopportunitiesforbreastandovariancancers AT francescapentimalli emergingroleofcyclindependentkinaseinhibitorsintreatingdietinducedobesitynewopportunitiesforbreastandovariancancers |